Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes
|Published in||Mediators of Inflammation. 2014, vol. 2014, p. 162021|
|Abstract||In type 2 diabetes, hyperglycemia, insulin resistance, increased inflammation, and oxidative stress were shown to be associated with the progressive deterioration of beta-cell function and mass. Short-chain fatty acids (SCFAs) are organic fatty acids produced in the distal gut by bacterial fermentation of macrofibrous material that might improve type 2 diabetes features. Their main beneficial activities were identified in the decrease of serum levels of glucose, insulin resistance as well as inflammation, and increase in protective Glucagon-like peptide-1 (GLP-1) secretion. In this review, we updated evidence on the effects of SCFAs potentially improving metabolic control in type 2 diabetes.|
|Keywords||Animals — Diabetes Mellitus, Type 2/metabolism — Fatty Acids, Volatile/metabolism — Gastrointestinal Tract/microbiology — Glucose/metabolism — Humans — Microbiota/physiology|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research group||L'athérosclérose et ses complications cliniques (591)|
|PUDDU, Alessandra et al. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. In: Mediators of Inflammation, 2014, vol. 2014, p. 162021. https://archive-ouverte.unige.ch/unige:77531|